Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.
Schrock AB, Ouyang C, Sandhu J, Sokol E, Jin D, Ross JS, Miller VA, Lim D, Amanam I, Chao J, Catenacci D, Cho M, Braiteh F, Klempner SJ, Ali SM, Fakih M.
Schrock AB, et al. Among authors: sandhu j.
Ann Oncol. 2019 Jul 1;30(7):1096-1103. doi: 10.1093/annonc/mdz134.
Ann Oncol. 2019.
PMID: 31038663
Free article.